Considering the similarities in PC between ALS and MS [17,18,42], and PAD2 targeting reduces citrullination and disease phenotypes in the latter [81], PAD inhibition may elicit similar beneficial outcomes in ALS. Here, PADI2 is linked to myeloid sarcoma.